TY - JOUR T1 - Population-level management of Type 1 diabetes via continuous glucose monitoring and algorithm-enabled patient prioritization: Precision health meets population health JF - medRxiv DO - 10.1101/2021.05.04.21256647 SP - 2021.05.04.21256647 AU - Johannes O. Ferstad AU - Jacqueline J. Vallon AU - Daniel Jun AU - Angela Gu AU - Anastasiya Vitko AU - Dianelys P. Morales AU - Jeannine Leverenz AU - Ming Yeh Lee AU - Brianna Leverenz AU - Christos Vasilakis AU - Esli Osmanlliu AU - Priya Prahalad AU - David M Maahs AU - Ramesh Johari AU - David Scheinker Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/05/08/2021.05.04.21256647.abstract N2 - Objective To develop and scale algorithm-enabled patient prioritization to improve population-level management of type 1 diabetes (T1D) in a pediatric clinic with fixed resources, using telemedicine and remote monitoring of patients via continuous glucose monitor (CGM) data review.Research Design and Methods We adapted consensus glucose targets for T1D patients using CGM to identify interpretable clinical criteria to prioritize patients for weekly provider review. The criteria were constructed to manage the number of patients reviewed weekly and identify patients who most needed provider contact. We developed an interactive dashboard to display CGM data relevant for the patients prioritized for review.Results The introduction of the new criteria and interactive dashboard was associated with a 60% reduction in the mean time spent by diabetes team members who remotely and asynchronously reviewed patient data and contacted patients, from 3.2±0.20 to 1.3±0.24 minutes per patient per week. Given fixed resources for review, this corresponded to an estimated 147% increase in weekly clinic capacity. Patients who qualified for and received remote review (n=58) have associated 8.8 percentage points (pp) (95% CI = 0.6–16.9pp) greater time-in-range (70-180 mg/dL) glucoses compared to 25 control patients who did not qualify at twelve months after T1D onset.Conclusions An algorithm-enabled prioritization of T1D patients with CGM for asynchronous remote review reduced provider time spent per patient and was associated with improved time-in-range.Competing Interest StatementDr Maahs has had research support from the NIH, JDRF, NSF, and the Helmsley Charitable Trust and his institution has had research support from Medtronic, Dexcom, Insulet, Bigfoot Biomedical, Tandem, and Roche. Dr Maahs has consulted for Abbott, Aditxt, the Helmsley Charitable Trust, Sanofi, Novo Nordisk, Eli Lilly, Medtronic, Insulet, and Dompe. None of the other authors have competing interests to declare.Funding StatementThis work was supported by R18DK122422 and P30DK116074.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Stanford University IRB: IRB-48935, IRB-49192, IRB-52812, IRB-56451All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSome of the summary data are available at request from the corresponding author. The raw patient data is protected by privacy laws and cannot be shared. ER -